|
|
Volumn 18, Issue 1, 2000, Pages 19-
|
|
Isis and antisense face crucial test without Novartis
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FOMIVIRSEN;
AIDS RELATED COMPLEX;
CLINICAL TRIAL;
CYTOMEGALIC INCLUSION BODY DISEASE;
DRUG RESEARCH;
FINANCIAL MANAGEMENT;
GENE TECHNOLOGY;
GENE THERAPY;
HUMAN;
MARKETING;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RETINITIS;
SHORT SURVEY;
ANTISENSE ELEMENTS (GENETICS);
BIOTECHNOLOGY;
CALIFORNIA;
CLINICAL TRIALS;
DRUG INDUSTRY;
HUMANS;
MARKETING OF HEALTH SERVICES;
|
|
EID: 0033987884
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/71852 Document Type: Short Survey |
|
Times cited : (8)
|
|
References (0)
|